Trial Profile
A Study to Evaluate the Effect of Intravitreal Ranibizumab on Intraocular Concentrations of Vascular Endothelial Growth Factor-A and Pigment Epithelium-Derived Factor in Patients With Neovascular Glaucoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Glaucoma
- Focus Pharmacodynamics
- 23 Mar 2016 New trial record